FARMACIA HOSPITALARIA最新文献

{"title":"Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study","authors":"Esther Chamorro-de-Vega ,&nbsp;Alberto Calvo ,&nbsp;María Fernández-Pacheco ,&nbsp;Belén Hernández-Muniesa ,&nbsp;Rosa Romero-Jiménez ,&nbsp;Araceli Casado-Gómez ,&nbsp;Esther Ramírez ,&nbsp;Grupo de Trabajo Estudio SACVINFA:,&nbsp;Alberto Morell ,&nbsp;Nuria Herrero ,&nbsp;Bárbara Úbeda ,&nbsp;Arantza Ais-Larisgoitia ,&nbsp;Elena Lobato-Matilla ,&nbsp;Álvaro Muñoz ,&nbsp;Miguel Ángel Casado ,&nbsp;Vicente Escudero-Vilaplana","doi":"10.1016/j.farma.2024.04.006","DOIUrl":"10.1016/j.farma.2024.04.006","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate health-related quality of life perceived by patients with the most prevalent immune-mediated inflammatory diseases in Spain: inflammatory bowel disease (IBD), psoriasis (Ps), psoriatic arthritis (AP), rheumatoid arthritis (RA), and spondyloarthropathies (SpAs), and to determine the factors that influence patient quality of life.</div></div><div><h3>Methods</h3><div>The SACVINFA study (SA<!--> <!-->=<!--> <!-->satisfaction, CV<!--> <!-->=<!--> <!-->quality of life, IN<!--> <!-->=<!--> <!-->immune-mediated, FA<!--> <!-->=<!--> <!-->pharmacy) consisted of an observational study conducted in 4 hospitals in the Community of Madrid. A cross-sectional analysis was made for adult patients diagnosed with an immune-mediated inflammatory disease who attended the Pharmacy Service. Quality of life was assessed using the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and specific questionnaires: SIBDQ-9, DLQI, PsAQoL, QoL-RA, and ASQoL.</div></div><div><h3>Results</h3><div>A total of 578 patients were analysed (inflammatory bowel disease<!--> <!-->=<!--> <!-->25.3%; psoriasis<!--> <!-->=<!--> <!-->19.7%; spondyloarthropathies<!--> <!-->=<!--> <!-->18.7%; rheumatoid arthritis<!--> <!-->=<!--> <!-->18.5%; psoriatic arthritis<!--> <!-->=<!--> <!-->17.8%). The mean age (standard deviation) was 49.8 (12.3) years and 50.7% were male. The average score (standard deviation) for the global EQ-5D-5L was 0.771 (0.2) and the mean (standard deviation) visual analogue scale score was 71.5 (20.0). Type of immune-mediated inflammatory diseases was associated with differences in quality of life showing psoriasis and inflammatory bowel disease higher values of EQ5D-5L than psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies, <em>p</em> <!-->&lt;.05 in all comparisons. Patients with RA, IBD, and Ps achieved 70% of the maximum score, while patients with PsA and SpAs did not reach 50% of the maximum possible score.</div><div>Female gender, a state of moderate/severe disease severity, an older age, and a higher number of previous treatments were correlated with worse quality of life. Conversely, persistence to current treatment correlated with better quality of life.</div></div><div><h3>Conclusions</h3><div>Patients with immune-mediated inflammatory diseases have markedly affected quality of life, mainly in the pain/discomfort dimension, especially in those immune-mediated inflammatory diseases with a rheumatological component.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages 265-271"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141092265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population","authors":"Cristina Galindo García ,&nbsp;Rocío Díaz Acedo ,&nbsp;Silvia Artacho Criado ,&nbsp;María Rodríguez de la Borbolla Artacho","doi":"10.1016/j.farma.2024.03.014","DOIUrl":"10.1016/j.farma.2024.03.014","url":null,"abstract":"<div><h3>Objective</h3><div>Triple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the effectiveness and safety of neoadjuvant treatment in early-stage triple-negative breast cancer and to identify predictors of pathological complete response.</div></div><div><h3>Methods</h3><div>This is a single-center, retrospective study involving 79 patients with triple-negative breast cancer who initiated neoadjuvant treatment between January 2017 and October 2022. Descriptive analyses were performed as appropriate. Statistical analysis utilized bivariate logistic regression to explore the presence of factors related to pathological complete response, and the Kaplan–Meier method was employed for survival analysis.</div></div><div><h3>Results</h3><div>In the overall population, 27 patients (<em>n</em> <!-->=<!--> <!-->78; 34.6%) achieved pathological complete response in the breast and axillary lymph nodes, and 31 (<em>n</em> <!-->=<!--> <!-->73; 42.5%) achieved a grade 5 pathological complete response in the breast, according to the Miller and Payne classification. The addition of platinum to standard therapy improved both breast and axillary lymph node pathological complete response rates. Age less than 40 years was identified as a predictor of pathological complete response in our study population through bivariate analysis, while Ki67 levels lower than 70% were associated with a lower pathological complete response rate. Adverse events were reported in 72 patients (91.1%), with grade 3–5 adverse events observed in 33 (41.8%). There was a particularly notable increase in gastrointestinal and hematological adverse events when platinum was added.</div></div><div><h3>Conclusions</h3><div>In this population, we observed moderate rates of pathological complete response with acceptable chemotherapy tolerance. Platinum-based chemotherapy appears to enhance the likelihood of achieving pathological complete response, albeit with a less favorable safety profile. Therefore, evaluating the benefit–risk balance is crucial when selecting the optimal chemotherapy regimen for individual patients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages 278-285"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Treatment of juvenile recurrent respiratory papillomatosis in a pediatric lung transplant recipient","authors":"Laura Gómez-Ganda ,&nbsp;Ignacio Iglesias-Serrano ,&nbsp;Carlos Javier Parramón-Teixidó ,&nbsp;Laura Batlle-Masó ,&nbsp;José Antonio Peña-Zarza ,&nbsp;Ana Díez-Izquierdo","doi":"10.1016/j.farma.2024.04.013","DOIUrl":"10.1016/j.farma.2024.04.013","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages T313-T315"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Intrathecal injection of fluorescein for localisation of cerebrospinal fluid fistula","authors":"Isabel Carreño Dato ,&nbsp;Carmen Matoses Chirivella ,&nbsp;Lara Peral Ballester ,&nbsp;Daniel García Sánchez ,&nbsp;Sergio Maciá Soriano ,&nbsp;Andrés Navarro Ruiz","doi":"10.1016/j.farma.2024.05.006","DOIUrl":"10.1016/j.farma.2024.05.006","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages T310-T312"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tratamiento de la papilomatosis recurrente respiratoria juvenil en un paciente pediátrico receptor de trasplante pulmonar","authors":"Laura Gómez-Ganda ,&nbsp;Ignacio Iglesias-Serrano ,&nbsp;Carlos Javier Parramón-Teixidó ,&nbsp;Laura Batlle-Masó ,&nbsp;José Antonio Peña-Zarza ,&nbsp;Ana Díez-Izquierdo","doi":"10.1016/j.farma.2024.02.008","DOIUrl":"10.1016/j.farma.2024.02.008","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages 313-315"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administración intratecal de fluoresceína para la localización de las fístulas de líquido cefalorraquídeo","authors":"Isabel Carreño Dato ,&nbsp;Carmen Matoses Chirivella ,&nbsp;Lara Peral Ballester ,&nbsp;Daniel García Sánchez ,&nbsp;Sergio Maciá Soriano ,&nbsp;Andrés Navarro Ruiz","doi":"10.1016/j.farma.2024.03.003","DOIUrl":"10.1016/j.farma.2024.03.003","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages 310-312"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Implementation of a traceability and safe drug preparation system in a clean room","authors":"Marta Echávarri de Miguel,&nbsp;Belén Riva de la Hoz,&nbsp;Margarita Cuervas-Mons Vendrell,&nbsp;Beatriz Leal Pino,&nbsp;Luis Fernandez Romero","doi":"10.1016/j.farma.2024.05.003","DOIUrl":"10.1016/j.farma.2024.05.003","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the process of implementing a traceability and safe manufacturing system in the clean room of a pharmacy service to increase patient safety, in accordance with current legislation.</div></div><div><h3>Methods</h3><div>The process was carried out between September 2021 and July 2022. The software program integrated all the recommended stages of the manufacturing process outlined in the “Good Practices Guide for Medication Preparation in Pharmacy Services” (GBPP). The following sections were parameterised in the software program: personnel, facilities, equipment, starting materials, packaging materials, standardised work procedures, and quality controls.</div></div><div><h3>Results</h3><div>A total of 50 users, 4 elaboration areas and 113 equipments were included. 435 components were parameterized (195 raw materials and 240 pharmaceutical specialties), 54 packaging materials, 376 standardised work procedures (123 of them corresponding to sterile medicines and 253 to non-sterile medicines, of which 52 non-sterile were dangerous), in addition, 17 were high risk, 327 medium risk, and 32 low risk, and 13 quality controls.</div></div><div><h3>Conclusions</h3><div>The computerization of the production process has allowed the implementation of a traceability and secure manufacturing system in a controlled environment in accordance with current legislation.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages T290-T293"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Characteristics, clinical benefit, and reimbursement of new authorisations for oncohaematology drugs in Spain between 2017 and 2020","authors":"Hilario Martínez-Barros ,&nbsp;Álvaro Pousada-Fonseca ,&nbsp;Jorge Pedreira-Bouzas ,&nbsp;Ana Clopés-Estela","doi":"10.1016/j.farma.2024.07.006","DOIUrl":"10.1016/j.farma.2024.07.006","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the authorisations and funding resolutions for new onco-haematological drugs in Spain between 2017 and 2020, as well as the results of their main trials.</div></div><div><h3>Methods</h3><div>Observational, cross-sectional, descriptive study conducted between October and December 2022. Onco-haematology drugs approved by the European Medicines Agency between 2017 and 2020 were included, according to EFPIA patients W.A.I.T Indicator 2021 Survey. Authorisation information was obtained from the main study of the European Public Assessment Report. Data were collected on medicines, their authorisation and main study, benefit shown, cost, and status and time to reimbursement.</div></div><div><h3>Results</h3><div>Forty-one new drugs authorised for 49 indications were identified. More than half (58.5%) were targeted therapies, and 61.2% were for the treatment of solid tumours (61.2%). Most had palliative intent (71.4%) and were indicated in relapsed or refractory disease (55.1%). Of the clinical trials, 57.1% were phase III and 63.3% were randomised. The primary endpoint was overall survival in 16.3%, increasing to 25.8% among randomised clinical trials. Regarding licensed drugs based on response rate, the median response rate was 56.4% [IQI 40–66.3]. In those authorised on the basis of surrogate time-to-event endpoints, the median hazard ratio was 0.54 [IQI 0.38–0.57], and among those using overall survival was 0.71 [IQI 0.59–0.77]. Globally, 22.4% had shown benefit in overall survival, with a median gain of 4 months [IQI 3.6–16.7]. One-third (33.3%) of the indications evaluable according to the European Society for Medical Oncology Magnitude of Clinical Benefit Scale showed substantial clinical benefit. Of the indications, 75.5% were funded, half (48.6%; 36.7% of the total) with restrictions. The median time to funding was 19.5 months [IQI 11.4–29.3].</div></div><div><h3>Conclusions</h3><div>Most main clinical trials of new onco-haematology drugs approved in Spain used surrogate primary endpoint and, at the time of authorisation, few had shown to prolong overall survival. More than a third were uncontrolled clinical trials.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages T272-T277"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] A quarter of a century of the VIH-SEFH group: Transforming care, facing challenges and reaffirming commitment","authors":"Ramón Morillo Verdugo ,&nbsp;Pilar Taberner Bonastre","doi":"10.1016/j.farma.2024.09.011","DOIUrl":"10.1016/j.farma.2024.09.011","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages T263-T264"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manejo terapéutico, adherencia y resultados clínicos de la insuficiencia cardiaca en Andalucía. Protocolo ANDALIC","authors":"Héctor Rodríguez-Ramallo ,&nbsp;Nerea Báez-Gutiérrez ,&nbsp;Didiana Jaramillo-Ruiz ,&nbsp;Gabriel Sanfélix-Gimeno ,&nbsp;Román Villegas-Portero ,&nbsp;José Luis Jiménez-Murillo ,&nbsp;Carlos Hernández-Quiles ,&nbsp;Bernardo Santos-Ramos","doi":"10.1016/j.farma.2024.03.002","DOIUrl":"10.1016/j.farma.2024.03.002","url":null,"abstract":"<div><div>Heart failure is a prevalent syndrome with high mortality rates, representing a significant economic burden in terms of healthcare. The lack of systematic information about the treatment and adherence of patients with heart failure limits the understanding of these aspects and potentially the improvement of clinical outcomes.</div></div><div><h3>Objective</h3><div>To describe the clinical characteristics, therapeutic management, adherence, persistence and clinical results, as well as the association between these variables, in a cohort of patients with heart failure in Andalusia.</div></div><div><h3>Design</h3><div>This study will be an observational, population-based, retrospective cohort study. Data of patients discharged from an Andalusian hospital with a diagnosis of heart failure between 2014 and 2023 will be extracted from the Andalusian population health database.</div></div><div><h3>Analysis</h3><div>The statistical analysis will incorporate the following strategies: 1) Descriptive analysis of the characteristics of the population cohort, adherence measures, and clinical outcomes. 2) Bivariate analyses to study the association of covariates with adherence, persistence and clinical results. 3) Multivariate logistic regression and Cox regression analysis including relevant covariates. 4) To evaluate changes over time, multivariate Poisson regression models will be used.</div><div>By conducting this comprehensive study, we aim to gain valuable insights into the clinical characteristics, treatment management, and adherence of heart failure patients in Andalusia, as well as to identify factors that may influence clinical outcomes. These findings could be critical both for the development of optimized strategies that improve medical care and quality of life of patients and for mitigating the health burden of HF in the region.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"48 6","pages":"Pages 294-298"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}